Skip to main content

Table 4 Associations between individual HLA-DRB1 haplotype and achieving good/moderate EULAR response, in overall RA, as well as in ACPA-positive RA and ACPA-negative RA

From: A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy – results from a Swedish cohort study

Haplotype Prevalence (%) Overall RA ACPA-positive RA ACPA-negative RA
PRAA 10.2 Reference Reference Reference
DFRE 1.7 1.60 (0.51–5.03) 1.60 (0.48–5.34) NA
GYRQ 4.8 0.59 (0.29–1.19) 0.64 (0.28–1.47) 0.18 (0.03–1.28)
LFEA 0.4 0.23 (0.04–1.55) NA NA
LFRA 14.9 0.89 (0.51–1.56) 0.93 (0.49–1.79) 0.33 (0.06–1.88)
PRRA 0.8 0.89 (0.20–3.94) 2.15 (0.23–20.28) NA
SGRA 1.7 0.72 (0.26–1.96) 0.81 (0.27–2.47) 0.28 (0.01–5.30)
SGRL 2.9 1.00 (0.41–2.43) 1.23 (0.37–4.10) 0.14 (0.02–0.95)
SSEA 5.4 0.92 (0.45–1.86) 1.31 (0.53–3.28) 0.12 (0.02–0.73)
SSKA 0.7 2.49 (0.29–21.30) NA 0.12 (0.01–2.59)
SSKR 9.3 0.99 (0.47–2.10) 1.23 (0.51–2.99) 0.04 (0.00–0.39)
SSRA 3.6 1.98 (0.78–5.00) 2.43 (0.81–7.32) 0.55 (0.06–5.03)
SSRE 1.1 1.59 (0.32–7.82) 2.58 (0.30–22.14) 0.10 (0.00–2.41)
VFRA 2.1 0.52 (0.21–1.24) 0.60 (0.22–1.63) 0.17 (0.01–2.84)
VHEA 0.3 1.14 (0.11–12.24) 1.58 (0.14–17.89) NA
VHKA 27.0 0.78 (0.46–1.32) 1.08 (0.59–1.97) 0.16 (0.03–0.93)
VHRA 11.9 1.10 (0.62–1.97) 1.20 (0.62–2.33) 0.93 (0.11–8.00)
VHRE 1.3 1.03 (0.31–3.43) 2.11 (0.43–10.35) 0.03 (0.00–0.55)
PAA 10.2 Reference Reference Reference
DRE 1.7 1.59 (0.51–5.01) 1.56 (0.47–5.20) NA
GRQ 4.8 0.59 (0.29–1.19) 0.63 (0.27–1.45) 0.19 (0.03–1.33)
LEA 0.4 0.23 (0.03–1.50) NA NA
LRA 14.9 0.89 (0.51–1.55) 0.93 (0.49–1.77) 0.34 (0.06–1.92)
PRA 0.8 0.90 (0.20–3.98) 2.11 (0.22–19.84) NA
SEA 5.4 0.95 (0.47–1.91) 1.36 (0.55–3.39) 0.13 (0.02–0.75)
SKA 0.7 2.62 (0.31–22.35) NA 0.13 (0.01–2.73)
SKR 9.3 1.01 (0.48–2.13) 1.26 (0.52–3.05) 0.05 (0.00–0.43)
SRA 5.3 1.34 (0.64–2.79) 1.51 (0.65–3.52) 0.48 (0.06–3.63)
SRE 1.1 1.52 (0.31–7.42) 2.47 (0.29–21.15) 0.10 (0.00–2.51)
SRL 2.9 0.94 (0.39–2.27) 1.20 (0.36–3.98) 0.13 (0.02–0.92)
VEA 0.3 1.15 (0.11–12.39) 1.56 (0.14–17.60) NA
VKA 27.0 0.77 (0.46–1.30) 1.06 (0.58–1.94) 0.15 (0.03–0.91)
VRA 14.0 0.95 (0.55–1.64) 1.04 (0.55–1.94) 0.64 (0.09–4.31)
VRE 1.3 1.03 (0.31–3.44) 2.08 (0.42–10.27) 0.04 (0.00–0.66)
  1. ACPA anti-citrullinated protein/peptide antibodies, RA rheumatoid arthritis, EULAR European League Against Rheumatism